ATE495238T1 - Iin vitro methode um eine potentielle reaktion eines tieres an einen agenten zu bestimmen - Google Patents

Iin vitro methode um eine potentielle reaktion eines tieres an einen agenten zu bestimmen

Info

Publication number
ATE495238T1
ATE495238T1 AT06848082T AT06848082T ATE495238T1 AT E495238 T1 ATE495238 T1 AT E495238T1 AT 06848082 T AT06848082 T AT 06848082T AT 06848082 T AT06848082 T AT 06848082T AT E495238 T1 ATE495238 T1 AT E495238T1
Authority
AT
Austria
Prior art keywords
dcs
cultured
transwell
populations
blood monocytes
Prior art date
Application number
AT06848082T
Other languages
English (en)
Inventor
Donald Drake
David Moe
Conan Li
Heather Fahlenkamp
Guzman Sanchez-Schmitz
Russell Higbee
Robert Parkhill
William Warren
Original Assignee
Vaxdesign Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxdesign Corp filed Critical Vaxdesign Corp
Application granted granted Critical
Publication of ATE495238T1 publication Critical patent/ATE495238T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/44—Fungal antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/02—Form or structure of the vessel
    • C12M23/12—Well or multiwell plates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/20—Material Coatings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
    • C12M25/02—Membranes; Filters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
    • C12M25/14—Scaffolds; Matrices
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Sustainable Development (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Clinical Laboratory Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT06848082T 2005-12-21 2006-12-21 Iin vitro methode um eine potentielle reaktion eines tieres an einen agenten zu bestimmen ATE495238T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75203305P 2005-12-21 2005-12-21
PCT/US2006/049128 WO2007076061A1 (en) 2005-12-21 2006-12-21 A porous membrane device that promotes the differentiation of monocytes into dendritic cells

Publications (1)

Publication Number Publication Date
ATE495238T1 true ATE495238T1 (de) 2011-01-15

Family

ID=37963795

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10151003T ATE531793T1 (de) 2005-12-21 2006-12-21 Eine poröse membran gerät, das die differenzierung von monozyten in dendritische zellen fördert
AT06848082T ATE495238T1 (de) 2005-12-21 2006-12-21 Iin vitro methode um eine potentielle reaktion eines tieres an einen agenten zu bestimmen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT10151003T ATE531793T1 (de) 2005-12-21 2006-12-21 Eine poröse membran gerät, das die differenzierung von monozyten in dendritische zellen fördert

Country Status (9)

Country Link
US (2) US20070178076A1 (de)
EP (2) EP2199384B1 (de)
JP (1) JP2009521228A (de)
AT (2) ATE531793T1 (de)
AU (1) AU2006330951B2 (de)
CA (2) CA2634119C (de)
DE (1) DE602006019638D1 (de)
IL (1) IL192090A (de)
WO (1) WO2007076061A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071373B2 (en) 2004-04-28 2011-12-06 Sanofi Pasteur Vaxdesign Corp. Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS)
US7785883B2 (en) 2004-04-28 2010-08-31 Vax Design Corp. Automatable artificial immune system (AIS)
US8298824B2 (en) 2004-04-28 2012-10-30 Sanofi Pasteur Vaxdesign Corporation Methods of evaluating a test agent in a diseased cell model
US7771999B2 (en) 2004-04-28 2010-08-10 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US7709256B2 (en) * 2004-04-28 2010-05-04 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US7785806B2 (en) 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
US7855074B2 (en) 2004-04-28 2010-12-21 Vaxdesign Corp. Artificial immune system: methods for making and use
US8030070B2 (en) * 2004-04-28 2011-10-04 Sanofi Pasteur Vaxdesign Corp. Artificial lymphoid tissue equivalent
ATE531793T1 (de) * 2005-12-21 2011-11-15 Sanofi Pasteur Vaxdesign Corp Eine poröse membran gerät, das die differenzierung von monozyten in dendritische zellen fördert
EP1969366B1 (de) 2005-12-21 2015-10-21 Sanofi Pasteur VaxDesign Corporation In-vitro-keimzentren
EP2043695B8 (de) * 2006-06-27 2012-02-29 Sanofi Pasteur VaxDesign Corporation Modelle für die bewertung von impfstoffen
US8647837B2 (en) * 2007-07-16 2014-02-11 Sanofi Pasteur Vaxdesign Corp. Artificial tissue constructs comprising alveolar cells and methods for using the same
AU2010225438A1 (en) * 2009-03-17 2011-10-13 The Heart Research Institute Ltd Method of cell differentiation and uses therefor in screening, diagnosis and therapy
JP2013517943A (ja) * 2010-01-29 2013-05-20 モレキュラー・インプリンツ・インコーポレーテッド ナノ粒子を形成するためのナノインプリントリソグラフィプロセス
EP2822578A4 (de) 2012-03-07 2015-10-07 Childrens Medical Center Gewebekonstrukte und verwendungen davon
US9423234B2 (en) 2012-11-05 2016-08-23 The Regents Of The University Of California Mechanical phenotyping of single cells: high throughput quantitative detection and sorting
FR3045664A1 (fr) * 2015-12-17 2017-06-23 Oreal Membrane pour tissu reconstruit comprenant des pores de plusieurs diametres
JP2019531717A (ja) * 2016-09-08 2019-11-07 サノフィ パスツール ヴァックスデザイン コーポレーション インビトロの新生児バイオミメティック（ｎｍｉｍｉｃ）モデル及び方法、並びにその使用
KR101986092B1 (ko) * 2016-09-13 2019-06-05 대한뉴팜(주) 유두진피 섬유아세포의 고순도 분리 방법
EP3545077A1 (de) * 2016-11-24 2019-10-02 AlveoliX AG Zellkultivierungssystem und -verfahren
WO2019002305A1 (en) * 2017-06-26 2019-01-03 BIOHOPE Scientific Solutions for Human Health S.L. METHOD OF PREDICTING AND MONITORING CLINICAL RESPONSE TO IMMUNOMODULATORY THERAPY
CN112221543B (zh) * 2019-07-15 2024-05-10 京东方科技集团股份有限公司 细胞片层转移器件、运输装置和转移细胞片层的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5160490A (en) * 1986-04-18 1992-11-03 Marrow-Tech Incorporated Three-dimensional cell and tissue culture apparatus
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5188959A (en) * 1989-09-28 1993-02-23 Trustees Of Tufts College Extracellular matrix protein adherent t cells
US5827641A (en) * 1992-11-13 1998-10-27 Parenteau; Nancy L. In vitro cornea equivalent model
US5695996A (en) * 1994-09-23 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Artificial organ culture system
US6479258B1 (en) * 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5739001A (en) * 1996-10-29 1998-04-14 E. I. Du Pont De Nemours And Company Solid phase cell-based assay
US6177282B1 (en) * 1997-08-12 2001-01-23 Mcintyre John A. Antigens embedded in thermoplastic
ATE428769T1 (de) * 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US20020155108A1 (en) * 1998-05-04 2002-10-24 Biocrystal, Ltd. Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
ATE405647T1 (de) * 1999-11-12 2008-09-15 Fibrogen Inc Rekombinantes gelatin in impstoffen
JP2003530826A (ja) * 1999-11-17 2003-10-21 ユニバーシティー オブ ロチェスター ヒトのエキソビボ免疫系
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
JP2004522446A (ja) * 2001-02-07 2004-07-29 コリア アトミック エネルギー リサーチ インスティテュート 上皮細胞の分離方法、細胞を前条件付けする方法、およびバイオ人工皮膚もしくは真皮を上皮細胞または条件付けされた細胞を用いて調製する方法
EP1437147B1 (de) * 2001-09-25 2012-06-27 National Institute for Environmental Studies Verfahren zur herstellung einer grundmembran
FR2833271B1 (fr) * 2001-12-10 2004-09-17 Coletica Production de cellules dendritiques in vitro a partir de monocytes cd14+, pour notamment la realisation de modeles cellulaires et/ou tissulaires en suspension, en monocouches et tridimentionnels; utilisation de ces modeles
GB0130789D0 (en) * 2001-12-21 2002-02-06 King S College London Application of spores
IL164661A0 (en) * 2002-03-18 2005-12-18 Vaxdesign Corp Dentritic cell nodes
ES2379252T3 (es) * 2002-04-11 2012-04-24 Cyclex, Inc. Método para monitorizar la respuesta inmunitaria y predecir los desenlaces clínicos en receptores de trasplantes
US20040009943A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
WO2004031361A2 (en) * 2002-10-03 2004-04-15 University Of Rochester Three-dimensional peripheral lymphoid organ cell cultures
US20040109876A1 (en) * 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV
US20070141552A1 (en) * 2004-04-28 2007-06-21 Warren William L Automatable artificial immune system (AIS)
US8030070B2 (en) * 2004-04-28 2011-10-04 Sanofi Pasteur Vaxdesign Corp. Artificial lymphoid tissue equivalent
US7771999B2 (en) * 2004-04-28 2010-08-10 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US20060275270A1 (en) * 2004-04-28 2006-12-07 Warren William L In vitro mucosal tissue equivalent
US7855074B2 (en) * 2004-04-28 2010-12-21 Vaxdesign Corp. Artificial immune system: methods for making and use
US8071373B2 (en) * 2004-04-28 2011-12-06 Sanofi Pasteur Vaxdesign Corp. Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS)
US7785806B2 (en) * 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
CA2564512C (en) * 2004-04-28 2014-03-18 Vaxdesign Corporation Artificial immune system: methods for making and use
US7785883B2 (en) * 2004-04-28 2010-08-31 Vax Design Corp. Automatable artificial immune system (AIS)
EP1969366B1 (de) * 2005-12-21 2015-10-21 Sanofi Pasteur VaxDesign Corporation In-vitro-keimzentren
ATE531793T1 (de) * 2005-12-21 2011-11-15 Sanofi Pasteur Vaxdesign Corp Eine poröse membran gerät, das die differenzierung von monozyten in dendritische zellen fördert
EP2043695B8 (de) * 2006-06-27 2012-02-29 Sanofi Pasteur VaxDesign Corporation Modelle für die bewertung von impfstoffen
EP2171455A4 (de) * 2007-07-06 2010-11-24 Vaxdesign Corp Schnelle erzeugung von t-zellen-unabhängigen antikörper-reaktionen auf t-zellen-abhängige antigene

Also Published As

Publication number Publication date
EP2199384A1 (de) 2010-06-23
EP1963491B1 (de) 2011-01-12
AU2006330951B2 (en) 2012-04-05
EP2199384B1 (de) 2011-11-02
EP1963491A1 (de) 2008-09-03
US20100105135A1 (en) 2010-04-29
AU2006330951A1 (en) 2007-07-05
CA2634119A1 (en) 2007-07-05
WO2007076061A1 (en) 2007-07-05
IL192090A0 (en) 2008-12-29
US20070178076A1 (en) 2007-08-02
IL192090A (en) 2012-01-31
CA2634119C (en) 2015-02-24
ATE531793T1 (de) 2011-11-15
DE602006019638D1 (de) 2011-02-24
CA2847310A1 (en) 2007-07-05
JP2009521228A (ja) 2009-06-04

Similar Documents

Publication Publication Date Title
ATE495238T1 (de) Iin vitro methode um eine potentielle reaktion eines tieres an einen agenten zu bestimmen
Shiota et al. Development of the fetal mouse palate in suspension organ culture
US12036272B2 (en) Antigen presenting scaffolds for immune-cell manipulation
Williams et al. Isolation and function of human dendritic cells
IL248493A0 (en) A method for increasing type 1 presentation of exogenous antigens using dendritic cells of human origin
IL195895A0 (en) Co-culture lymphoid tissue equivalent (lte) for an artificial immune system (ais)
JP2015180202A (ja) 人工免疫システム：作製および使用方法
Livingston et al. CD4 T-helper cell cytokine phenotypes and antibody response following tetanus toxoid booster immunization
Brabants et al. An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA–loaded dendritic cells for cancer vaccination
Sjaastad et al. Reduced T cell priming in microbially experienced “Dirty” mice results from limited IL-27 production by XCR1+ dendritic cells
US20230138095A1 (en) Scaffolds with stabilized mhc molecules for immune-cell manipulation
PL1951300T3 (pl) Zmiana równowagi TH1/TH2 w szczepionkach typu split przeciwko grypie zawierających adjuwant
DE60043781D1 (de) Verwendung allogener zelllinien zur beladung antigen-präsentierender zellen zur auslösung von immunantworten
AU2003288212A1 (en) Method to measure a T cell response and its uses to qualify antigen-presenting cells
Vremec et al. The purification of large numbers of antigen presenting dendritic cells from mouse spleen
Mori et al. Analysis of immunodominance among minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation
Reis et al. Naive donor responses to Schistosoma mansoni soluble egg antigens
Jian et al. Optimal conditions for adenoviral transduction of immature dendritic cells without affecting the tolerogenic activity of DC-based immunotherapy
Andrade et al. The long‐term impaired macrophages functions are already observed early after high‐dose ethanol administration
BRPI0619520A2 (pt) método para gerar células dendrìticas empregando temperatura reduzida
AR124432A1 (es) Procesamiento de linfocitos infiltrantes de tumor
RU2008136596A (ru) Способ определения напряженности клеточного поствакцинального иммунитета in vitro
Rodi et al. Effect of dendritic cell state and antigen-presentation
Barman et al. Immune-profiling of T helper 1 (Th1), Th2 and Th17 signatures in murine splenocytes by targeting intracellular cytokines
WO2026035682A1 (en) Lymphoid cell compositions, systems, and assays

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties